JBM (Healthcare) Limited (2161.HK)
HKD 1.85
(0.0%)
HKD 1.85
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.39 Million HKD | -126.59% |
| 2022 | 27.83 Million HKD | -80.57% |
| 2021 | 143.25 Million HKD | -17.45% |
| 2020 | 173.54 Million HKD | -55.91% |
| 2019 | 393.57 Million HKD | -33.87% |
| 2018 | 595.15 Million HKD | -3.09% |
| 2017 | 614.16 Million HKD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | -7.39 Million HKD | -126.59% |
| 2023 Q2 | 30.52 Million HKD | 0.0% |
| 2023 Q4 | -7.39 Million HKD | 0.0% |
| 2022 Q4 | 27.83 Million HKD | 0.0% |
| 2022 FY | 27.83 Million HKD | -80.57% |
| 2022 Q2 | 94.79 Million HKD | 0.0% |
| 2021 Q2 | 186.97 Million HKD | 0.0% |
| 2021 FY | 143.25 Million HKD | -17.45% |
| 2021 Q4 | 143.25 Million HKD | 0.0% |
| 2020 Q2 | - HKD | -100.0% |
| 2020 Q4 | 173.54 Million HKD | 0.0% |
| 2020 Q1 | 213.63 Million HKD | 0.0% |
| 2020 FY | 173.54 Million HKD | -55.91% |
| 2019 FY | 393.57 Million HKD | -33.87% |
| 2018 FY | 595.15 Million HKD | -3.09% |
| 2017 FY | 614.16 Million HKD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | -258.7 Million HKD | 97.14% |
| Grand Pharmaceutical Group Limited | 2.03 Billion HKD | 100.364% |
| Extrawell Pharmaceutical Holdings Limited | 5.94 Million HKD | 224.478% |
| Wai Yuen Tong Medicine Holdings Limited | 301.53 Million HKD | 102.454% |
| Qianhai Health Holdings Limited | -19.03 Million HKD | 61.136% |
| Lee's Pharmaceutical Holdings Limited | 30.94 Million HKD | 123.908% |
| Essex Bio-Technology Limited | -219.22 Million HKD | 96.625% |
| Tongfang Kontafarma Holdings Limited | 256.16 Million HKD | 102.888% |
| PuraPharm Corporation Limited | 377.54 Million HKD | 101.96% |
| SSY Group Limited | 1.71 Billion HKD | 100.432% |
| Jacobson Pharma Corporation Limited | 337.44 Million HKD | 102.193% |
| China Resources Pharmaceutical Group Limited | 50.97 Billion HKD | 100.015% |